To finalize its agreement with the U.S. Department of Justice, Mallinckrodt plc, of Staines-Upon-Thames, U.K., will pay $15.4 million to resolve a civil False Claims Act investigation of Questcor Pharmaceuticals Inc.'s legacy sales and marketing activities. Mallinckrodt acquired Questcor in August 2014. The agreement contains no admission of wrongdoing. Acthar Gel (repository corticotropin injection) was the centerpiece of Mallinckrodt's $5.6 billion acquisition of Questcor. 

No Comments